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Human leukocyte antigens (HLA) are important biomarkers because multiple diseases,
drug toxicity, and vaccine responses reveal strong HLA associations. Current clinical HLA
typing is an elimination process requiring serial testing. We present an alternative in situ
synthesized DNA-based microarray method that contains hundreds of thousands of probes
representing a complete overlapping set covering 1,610 clinically relevant HLA class I alle-
les accompanied by computational tools for assigning HLA type to 4-digit resolution. Our
proof-of-concept experiment included 21 blood samples, 18 cell lines, and multiple con-
trols. The method is accurate, robust, and amenable to automation. Typing errors were
restricted to homozygous samples or those with very closely related alleles from the same
locus, but readily resolved by targeted DNA sequencing validation of flagged samples.
High-throughput HLA typing technologies that are effective, yet inexpensive, can be used
to analyze the world’s populations, benefiting both global public health and personalized
health care.
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INTRODUCTION
The human leukocyte antigen (HLA) genomic region contains 12
protein coding genes (HLA-A, B, C, DRA1, DRB1, DRB3, DRB4,
DRB5, DQA1, DQB1, DPA1, and DPB1) and over 7,000 allelic
variants that regulate immune responses and other important
molecular and cellular processes (1). HLA is under a strong selec-
tion pressure in human beings, and is subject to rapid genetic
divergence to afford protection of interbreeding populations from
the emerging or pandemic diseases (2). Associations between HLA
and many diseases have been established (1, 3–7). HLA is one
of the most critical biomarkers in humans of broad relevance
for transplantation (3), transfusion medicine (4), cancer (6), and
identification of drug toxicity (7). The HLA region encoding clas-
sical transplantation genes is the most diverse within the human
genome. The resulting complexity limits our current ability to per-
form related large-scale population studies. Accurate population-
based HLA typing will enable the development of new methods
for risk assessment, early diagnosis, prognosis, and optimization
of therapies for many diseases.
Current HLA typing uses PCR amplification with sequence-
specific oligonucleotide probes (SSOP) in combination with
sequence-specific primer (SSP) testing and DNA or RNA sequenc-
ing. The SSOP method requires a large number of probes and
a series of separate hybridization reactions. These probes may
be arranged into arrays to be used in Luminex-based HLA typ-
ing (8). DNA microarrays were reported as a variant of the
SSOP method (9–11), but have not been used in clinical typ-
ing. SSP methods rely on a “yes/no” signal for amplification
based upon pairs of PCR primers that detect one or two infor-
mative single nucleotide polymorphisms (SNPs) for each reac-
tion. A large number of reactions and primer pairs are nec-
essary to include or exclude known HLA alleles. Sequencing
methods deploy PCR amplification of target loci followed by
DNA sequencing. Recently, next generation sequencing meth-
ods have been used for ultra-high resolution HLA typing using
both DNA (12) and RNA (13) sequencing. The standard RNA-
Seq approach used for HLA typing showed limited sensitivity
(94%) (14). DNA-based HLA typing approaches are currently
the methods of choice, but they are labor intensive and are usu-
ally limited to typing exons 2 and 3. RNA-based approaches
offer a simpler alternative to genomic DNA sequencing as they
focus on transcripts that reveal gene expression levels. RNA-based
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Table 1 |The count of HLA genes, proteins, null alleles, and their
prevalence in the World’s population.
Numbers of named HLA alleles (as of February 2014)
Observed Class I loci Genes Proteins Nulls
All A 2,432 1, 740 117
B 3,086 2, 329 101
C 2,035 1, 445 57
In population A 733 24
B 921 9
C 429 7
90% Coverage of global
HLA alleles
A 15
B 33
C 13
95% Coverage of global
HLA alleles
A 22
B 47
C 17
99% Coverage of global
HLA alleles
A 28
B 63
C 20
About 99% of HLA present in human population are covered by only 111 HLA alle-
les (1,17). Only 230 protein variants of HLA Class I are present in global population
at frequencies >0.01% (data not shown).
methods can be automated and are more cost effective than DNA
sequencing (15).
Ultra-sensitive and highly parallel methods allow for concur-
rent typing of multiple samples and are amenable to typing of
large number of individuals. The technologies are currently rapidly
evolving requiring constant updating of reagents, sample prepara-
tion, and methods refinement. Ideal HLA typing method must
yield a rapid turnaround, be highly accurate, and cost afford-
able. To ensure standardization, the process should be automatable
using robotics for sample preparation and processing (13). Here,
we describe a high-throughput method for HLA-A, -B, and -C
typing that utilizes hundreds of thousands of SSOPs that com-
pletely cover the vast majority of HLA alleles observed in human
population.
MATERIALS AND METHODS
Most of HLA diversity is encoded by the class I region – more than
5,500 protein variants that code HLA-A, -B, and -C molecules have
been reported (16). About 230 Class I HLA alleles are present in
the human population at allele frequencies of >0.01% and 111
cover >99% of global HLA alleles present in human population
(16, 17) (Table 1). The combinatorial complexity of HLA makes its
study difficult (Figure 1). The set of HLA alleles that were arrayed
on the HLA chip includes 505 genetic HLA-A, 703-B, and 402-C
variants encoding 159, 281, and 123 respective protein variants.
ALLELES, SAMPLES AND PROBES
The total number of named HLA alleles includes >7,500 genetic
sequences and> 5,500 proteins (Table 1). Alleles included in the
microarray design are shown in Table S1 in Supplementary mate-
rial. All control samples are shown in Table S2 in Supplementary
material. The numbers of probes that correspond to HLA-A, -B,
and -C alleles are shown in Table 2. The set of HLA alleles that
were arrayed on the HLA chip includes 505 genetic HLA-A, 703-B,
and 402-C variants encoding 159, 281, and 123 respective protein
variants. The sequences of these HLA variants were taken from the
HLA-IMGT database (18).
SAMPLE PREPARATION AND PROCESSING
The preparation and processing steps included RNA extraction,
cDNA synthesis, cRNA synthesis with amplification, cRNA purifi-
cation, preparation of hybridization samples, hybridization, wash,
scan, and feature extraction. The RNA from each sample was
extracted using the QIAGEN RNeasy Mini Kit. Quality control
was performed with the Agilent RNA 6000 Nano Kit. Fluores-
cent cRNA samples for hybridization were synthesized from 50 ng
total RNA using the Agilent single color direct labeling kit in
which cRNA was synthesized in the presence of Cy3 conjugated
NTPs. Samples were hybridized to custom slides at 64°C for
17 h, based on the Tm of 64.2°C. The slides were scanned using
an Agilent Microarray scanner. The signals from high intensity
fluorescent cRNA probes were measured from the spots shown
in green (Figure 2B). Sample preparation and processing and
subsequent computational analysis were performed strictly in a
double-blinded fashion.
SIGNAL PROCESSING – NORMALIZATION, ERROR CORRECTION AND
PROBE ANALYSIS
Following hybridization, arrays were scanned using Agilent high-
resolution GeneArray scanner at 2µm resolution. The initial
processing used Agilent Feature Extraction Software (http://www.
chem.agilent.com/library/usermanuals/public/g4460-90039_feat
ureextraction_user.pdf). The raw data signals showed significant
variability between individual slides. The ranges of the raw indi-
vidual array signals varied widely (Min to Max) from 2 to 47,174
or from 2 to 770,759 (Table S3 in Supplementary material). Signal
preprocessing included three steps: normalization, error estima-
tion, and error correction. Data normalization ensured that signals
from all arrays are mutually comparable. The normalization that
mapped signals to a scale of 1–20,000 with average signal being
1,000 was performed – the minimum was set to 1, maximum to
20,000, and the array-wide average to 1,000. Signals from each
array were subjects to several transformations. First, we calculated
the minimum raw probe signal of the entire array, Rmin. Then
we selected a scaling factor F, to ensure that the average of the
normalized signals is 1,000. A probe raw signal is designated as S
and its normalized signal as Sn. The normalization was a linear
transformation of all signals to the scale 1–20,000 using formula:
Sn = min(S − Rmin+ F , F × 20000)
F
Error correction was performed using detection of outliers and
correction of noisy signals. The analysis of overlapping probes
within a given window showed that the positive signals normally
show smooth change between consecutive probes, and negative
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FIGURE 1 |The complexity of study of HLA. (A) HLA resides at the short
arm of human chromosome 6 spreading over approximately 4 million base
pairs. (B) Class I region has three classical loci (A, B, and C loci) and each of
them has eight exons. Each individual has two copies of each locus.
(C) Sometimes HLA genes are mutated to produce null alleles resulting in
non-functional protein products. The example A*01:04N shows an insertion of
C in codon 186 (left arrow) that caused a frameshift resulting in a premature in
frame stop codon (right arrow). (D) HLA alleles are highly similar, and typically
have >85% identity across A, B, and C loci. The B7/B35 example shows
ambiguity – when two probes are positive, the result is ambiguous. In this
case both B*07:02/B*35:03 and B*07:24/B*35:33 are possible. However,
B*07:24 and B*35:33 alleles are rare, they have been observed in
frequencies of >0.0001% making it highly unlikely that this combination is
present in any one individual. On the other hand B*07:02 and B*35:03 have
been observed in all of the 22 populations screened in the NMDP and their
frequencies range from 0.8-13.1% (B*07:02) and 0.04-7.2% (B*35:03).
(E) More than 5,000 classic HLA Class I alleles have been identified in the
World population. The exclusion of null alleles, other problematic alleles, and
low-frequency alleles resulted in 1,687 clinically relevant HLA class I alleles.
These alleles combine into >45,000 A-B-C haplotypes.
signals have low values. Positive signals were defined by an allele-
specific threshold. Initially, the threshold was set as 10% of max-
imal signal for a given probe. With the accumulation of data, the
threshold was determined empirically from the measurement of
specific probes and integrated in the knowledge base (Figure S1 in
Supplementary material).
Duplication of probes on the array enabled us to assess the
occurrence of random errors and patterns of random errors.
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Table 2 | HLA class I coverage of the HLA microarray with probe
numbers.
Locus HLA-A HLA-B HLA-C HLA-E,
-F, -G
Total
Number of arrayed
sequences
505 703 402 77 1, 687
Number of probes 36, 003 36, 651 28, 320 6, 771 91, 661
Number of unique
probes
11, 980 12, 216 9, 432 5, 222 33, 469
Uninformative probes were identified by comparing the signals
of each probe across the 60 arrays.
COMPUTATIONAL ANALYSIS
For each array, we used a computational approach to analyze all
probe signals to determine the most likely HLA Class I geno-
types. The computational approach involves three steps: serotype
determination, genotype determination, and ambiguity removal.
In serotype determination, all serotypes were ranked based on
the average number of negative signals for each individual allele.
Serotypes that are present in a given sample tend to have smaller
average number and an absent serotype by contrast tends to have
larger average number of negative probes. Based on this analysis,
we could exclude a large number of serotypes that were actually
absent. However, not all absent serotypes have a larger number
of negative signals because of probe masking (a probe may be
present because it is shared with other allele present in the sam-
ple, Figure 2D). In genotype determination, we performed both
serotype comparisons and allele comparisons to select alleles that
are most likely to be present. In cases where there were multiple
possible alleles after serotype/allele comparisons, we performed
genotype comparison to remove the ambiguities. The workflow
for the computational analysis is shown in Figure 2C.
Serotype determination
The goal of serotype determination was to maximally reduce
the search space by eliminating irrelevant serotypes and ensure
that this step does not produce any false negatives. The proce-
dure involved four steps and is performed separately for each of
the loci (HLA-A, -B, and -C). These steps were data preprocess-
ing, serotype ranking, homozygotes determination, and redundant
serotype reduction.
Preprocessing. To efficiently assign HLA Class I genotype, there
were 1,687 clinically relevant alleles in total (505 HLA-A, 703-B,
and 402-C alleles). These alleles were covered by 33,469 unique
probes. Each probe covered a stretch of 20–60 nucleotides from
and its signal was assigned to the starting position. We made a
multiple sequence alignment for all the 1,687 allele sequences, to
help calculate the signal threshold at each position for HLA-A, -B,
and -C alleles, respectively.
Serotype ranking. The 563 sequences representing HLA-A, -B,
and -C alleles were grouped into 21 HLA-A serotypes, 36-B and 14-
C serotypes. The Neg(x) represent the number of negative probe
signals for allele x, and Neg(ST) represent the average number
of negative probe signals for serotype ST. We ranked all Neg(x)
that belong to same serotype ST in ascending order and selected k
alleles to calculate Neg(ST).
Neg(ST) =
∑
Neg(x)/k,
where k =Max(5,N ),N is the number of alleles in serotype ST.
When we applied this equation to all present and absent
serotypes among the samples, we found that Neg(ST) can effec-
tively differentiate present from absent serotypes. Most of the
present serotypes in the samples rank the first or the second in
each locus.
There were 472 present serotypes among the samples and 241
of them ranked the first, and 155 ranked the second, while 76
ranked lower (Table S4 in Supplementary material). From the
analysis of serotype ranking, we noted that most serotypes ST
have a clear boundary of Neg(ST) that distinguishes presence and
absence, while some serotypes do not have a clear boundary due to
probe masking or because they belong to the same supertype. For
example, Figure S2 in Supplementary material shows the distrib-
utions of Neg(A*01) and Neg(A*03). A*01 has a clear boundary
between A*01+ (present) and A*01− (absent). However, some
arrays with absent A*03 have a lower number of negative signals
due to probe masking when A*11 is present in that sample. The
average sequence identity between A*03 and A*11 is 98.9% and
they share a large number of probes. This is consistent with the
taxonomic classification that shows close relatedness of HLA-A*03
and -A*11, while A*01 is well separated from other serotypes (19).
Some serotypes, such as A03/A11, A26/A34/A43/A66, A23/A24,
and A31/A33/A74 show high sequence similarity. Therefore we
analyzed the Neg(ST) distribution of present and absent serotype
ST and define a MaxNeg(ST) to indicate the maximal Neg(ST) for
a present ST. The MaxNeg(ST) for all serotypes ST is shown in
Table S5 in Supplementary material.
Homozygocity. Homozygosis checking is an essential step for
HLA genotyping. In this study, we determined whether a locus
is homozygous or not based on the comparison of the best two
serotypes. We designated ST1 as the first ranking serotype of a
particular HLA locus L, and ST2 the second ranking. The locus L
is considered to be homozygous if Neg(ST2)−Neg(ST1)≥ 20. In
that case, we only keep ST1 and remove all the rest serotypes of
the locus L.
Redundant serotype elimination. If more than two serotypes
remain in the candidate list, we further remove serotypes by
using serotype comparison rules. In most cases, redundant
serotypes occur because of probe masking. We found that some
serotypes normally remain in the list in groups, for exam-
ple, a relatively well-distinguished A*01 and A*36. If one of
them is present, the other will be kept due to their sequence
similarities. Therefore, we derived serotype comparison rules
to deal with this ambiguity. Given two serotypes, ST1 and
ST2, we compare Neg(ST1) and Neg(ST2) and remove ST2 if
Neg(ST2)−Neg(ST1)>MaxDifference(ST1, ST2) and ST2 ranks
behind the second place. If the rule criterion is not met, it implies
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FIGURE 2 |The design of components of the HLA typing system.
(A) Probe design and matching melting temperatures were calculated for
each of the 75,476 probes (A, upper panel), melting temperatures of the initial
probes that were 25 nucleotides long (A, middle panel), melting temperature
for adjusted length probes targeting 64.2°C (A, lower panel). (B) Physical
design of the microarrays – each slide has four identical arrays, each having a
full set of probes covering full length of 1,687 Class I HLA sequences (left
image). The two images on the right show increasing magnification of signals
from fluorescent signal hybridization. The Agilent Feature Extraction program
was used to convert the fluorescence intensity of scanned arrays into text Cy
3 signal files. The Cy3 signals from hybridized high intensity fluorescent
samples were measured from the DNA probes organized as spots or
“features” on the array. At higher magnification the presence or absence of
fluorescent cRNA hybridization is evident (B, middle and right images
showing signals on a portion of one array). (C) Analytical workflow used
templates of known samples or a theoretically derived knowledgebase. The
three main steps include serotypes determination, genotypes determination,
and ambiguity removal. The input includes probes, probe signals, and HLA
sequences of target alleles. The output includes genotypes assigned by
template matching (see Figure 3 for details) or genotype matching with
ambiguity removal (described in the main text). (D) Sample 4 (Table 3) was
HLA-A*02:01/A*02:01, B*07:02/B*27:05, C*02:02/C*07:01 (A*02:01
homozygous). Probe signal analysis alone could not distinguish whether
DFCI-06 is heterozygous for HLA-A*02:01/02:16 or homozygous for either of
these alleles because this probe for A*02:01 is identical to (i.e., masked by)
C*07:01. Likewise, A*02:16 is masked by its associated HLA-B*07:02/
B*27:05/C*02:02 alleles. This issue can be resolved by a single Sanger
sequencing run for HLA-A2 locus around positions 610-630.
that either both ST1 and ST2 are present, or they cannot be
differentiated at the serotype level. Serotypes listed in Table S6
in Supplementary material usually cannot be differentiated at the
serotype level and are further analyzed. The remaining serotypes
ambiguities (more than two serotypes for each locus), if any, are
further analyzed in Genotype Determination step.
Genotype determination
The most probable alleles are determined from the remain-
ing serotypes. The genotyping was achieved by the comparison
with the templates in the knowledgebase (Figure 3), or when
unavailable, using the knowledge-based approach where theo-
retical patterns of negative probes were compared to the cor-
responding signals. In genotype determination, we combined
serotype comparisons and allele comparisons to select alleles that
were most likely present. When multiple alleles were possible
after serotype and individual allele comparisons, we performed
genotype comparison to remove the ambiguities. To apply these
methods, we first introduced the comparison vectors for serotypes
and alleles, and the comparison algorithm.
Serotype and allele comparison. The Serotype comparison vec-
tor is generated using the number of wins as we compare positive
and negative signal probes. The generation of an allele compari-
son vector is similar to that of serotype comparison vector though
the difference is we compare alleles within the same serotype and
determine the most likely allele by the number of wins. Allele com-
parison algorithm is used to estimate the number of wins of an
allele pair based on comparison of their signals. The serotype com-
parison vector Vs, is based on grouped serotypes according to their
average sequence similarities. Some serotypes are not very similar;
however, they frequently remain together on the candidate list. We
www.frontiersin.org November 2014 | Volume 5 | Article 597 | 5
Zhang et al. HLA typing by microarray
FIGURE 3 | Distribution of correlation coefficients between matched
and mismatched pairs and the number of serotype mismatches. (A)
Arrays that had duplicate samples in the knowledgebase (also seeTable 5)
paired with all other samples. The results show that all matches had zero
serotype mismatches. All mismatches had 2–12 serotype mismatches. (B)
Arrays that did not have duplicate samples in the knowledgebase of
templates all had 2–12 serotype mismatches. (C) Distribution of top 47
correlation coefficients segregated by matches, mismatches to repeat
samples (Mismatches 1, of 360 total), and mismatches of all other samples
(Mismatches 2, of 527 total). The Mismatches 1 correspond to data shown
in (A) and Mismatches 2 correspond to data shown in (B). In summary,
70% of matches can be determined from correlation coefficient alone
(r >0.975), and 100% of matches had no serotype mismatch. If r >0.95
and serotype mismatch number is 0, the identity of the query array to the
matching template from the knowledgebase can be established.
also consider those serotypes based on the observation of array
analysis. Our data set contains 21 HLA-A serotypes distributed
within nine serotype groups (serogroups), 36 HLA-B serotypes
within 17 groups, and 14 HLA-C serotypes within seven groups.
All possible serotypes that remain after the serotyping step are clus-
tered according to the predefined serogroups. If a serogroup has
two or more serotypes, we then generate a serotype comparison
vector Vs for all the involved alleles; if there is only one serotype in
a serogroup, we then generate an allele comparison vector Va for
every allele in that serotype. Comparison vectors Vs and Va con-
sist of all AvgWins(x) of every involved allele x and their number
of negative probe signals. A serotype/allele comparison vector can
be seen as a profile of the present serotypes and it represents the
signature of the actual probe signals.
Knowledgebase search. The comparison vectors based on same
alleles often share high correlation coefficients. Therefore, we can
identify the actual alleles by using knowledgebase search and
knowledge-based approach. The remaining serotypes are clustered
according to the serotype groups. We generate a comparison vector
for each serotype cluster. All the identified templates are ranked by
their correlation coefficients, and only the top N (N ≤ 5) are used
for genotyping of identified serotypes. If an allele is present in one
of the templates, it is considered a possible allele. In most cases,
the templates are very consistent with the alleles they represent.
Only the present alleles in the templates are kept while others are
removed. If a query serotype is not present, its profile can lead
to templates with no present alleles. We demonstrated that the
reproducibility is also observed on absent alleles. Based on the
high reproducibility of array data, the accumulation of more sam-
ples and expanded representation of HLA alleles and genotypes in
our knowledgebase, qualified templates for genotyping unknown
samples has high probability of being correctly identified.
Knowledge-based approach. Given a serotype, if we can-
not find any matching templates by doing a knowledgebase
search, the knowledge-based approach is used to select possi-
ble alleles x based on the allele comparison result, AvgWins(x)
and the number of negative probe signals, Neg(x). We define
Weight(x)=AvgWins(x)−Neg(x) to represent the overall signal
strength of x over the other alleles within the same serotype. If
x is a present allele, we can expect a high value of Weight(x) due
to relatively high AvgWins(x) and low Neg(x). On the contrary,
if x is an absent allele, we can expect a low value of Weight(x).
Each allele x is associated with a predefined WeightThreshold(x).
If Weight(x)>WeightThreshold(x), then we assume x is a possi-
ble present allele. Based on a comprehensive data analysis on all
the samples, we set an appropriate WeightThreshold(x) for each
allele x.
AMBIGUITY REMOVAL
There should be at most six alleles remaining after the analy-
sis within Serotype Determination and Genotype Determination
steps (two alleles for each HLA-A, -B, and -C, for a heterozygous
sample). However, in some cases there is a remaining ambiguity
resulting more than six HLA allele candidates. Such an ambigu-
ity can result in multiple combinations of possible genotypes. In
the Ambiguity Removal step we employ genotype comparison to
select the best combination. A genotype of HLA Class I consists of
at most two HLA-A, two -B, and two -C alleles. Based on this crite-
rion, we generate all possible combinations of genotypes according
Frontiers in Immunology | Alloimmunity and Transplantation November 2014 | Volume 5 | Article 597 | 6
Zhang et al. HLA typing by microarray
to the remaining alleles, and perform a pairwise comparison for
every pair of genotypes using the genotype comparison algorithm.
Genotype comparison algorithm
Genotype comparison algorithm is used to estimate the number
of wins of a genotype pair based on comparison of their signals.
Given two genotypes, G1 and G2, Sig(G1, p) represents the sig-
nal summation of all covered probes at position p of all involved
alleles in G1, and Sig(G2, p) represent the signal summation of
all covered probes at position p of all involved alleles in G2, and
Max(G1, G2, p) is the larger of Sig(G1, p) and Sig(G2, p). We
calculate the Wins(Gi) by comparing Gi with all the other geno-
types, and assign Wins(Gmax) as the maximal score, then report
all genotype combinations whose score above Wins(Gmax)− 20.
All the methods and steps within the Computational Analysis have
been automated and integrated into an HLA Class I genotyping
automation.
RESULTS
PROBE AND MICROARRAY DESIGN
We designed a microarray for highly parallel SSOP-based ultra-
sensitive HLA typing. The probe set was derived from observed
HLA sequences identified from the National Marrow Donor Pro-
gram (NMDP) (17). In contrast to earlier microarrays that used
a small number of ultra-specific probes designed to distinguish
between HLA variants (20), we utilized the complete overlapping
set of probes for target HLA sequences. The individual probes
were shifted by a single nucleotide along the full length of HLA
sequences. Each HLA array comprised 75,476 unique probes rep-
resenting 1,610 full-length HLA class I A, B and C sequences (505
HLA-A, 703 HLA-B, and 402 HLA-C alleles, Table S2 in Supple-
mentary material), and one negative control sequence. The design
also included probes for 1,439 class II sequences and 77 HLA-E, F,
and G alleles that were not analyzed in this study. A total of 175,611
probes were printed on each array. Initially, a starting overlapping
set of 25 nucleotide-long probes were selected – each position in
the 1,610 HLA class I sequences was represented by a unique probe.
A representative probe is shown in Figure 2A (top). The melting
temperature was calculated as follows:
Tm = 64.9+ 41× y + z − 16.4
w + x + y + z
Here, w, x, y, and z are the respective numbers of the bases A, T, G,
and C in the probe, respectively (21).
The range of TMs of these probes had 23 discrete values
between 41.3 and 77.4°C (Figure 2A, middle). Probe lengths
were adjusted to target melting temperature of Tm= 64.2°C. Each
probe was either extended or shortened to make its Tm as close
as possible to the target temperature (Figure 2A, bottom). The
adjusted length was 20–60 nucleotides, mandated by the Agilent
SurePrint technology (Agilent, Santa Clara, CA, USA) (22). We
used 60-mer SurePrint G3 Human CGH Microarray Kit, 4× 180 K
format to custom-design the microarrays. Probes were synthesized
directly from dNTPs on the array surface. Each slide had four
arrays (Figure 2B, left image). The array was designed using Agi-
lent eArray platform and manufactured. Microarrays were printed
on a standard (25 mm× 75 mm) glass slides.
HLA DETERMINATION
Of 21 blood samples, 19 were correctly typed for all loci (Table 3).
Only two of 126 HLA alleles were incorrectly assigned in the
blood samples. The two incorrect assignments (sample ID: 4 and
13) included the assignment of A*02:01/A*02:16 to an A*02:01
homozygous sample, and the assignment of C*07:01 to a C*07:06
sample. The alleles A*02:01 and A*02:16 have only two differ-
ent nucleotides at positions 559-60 (AC/GA). The alleles C*07:01
and C*07:06 only have one different nucleotide at position 1,061
(C/T). Five samples (2, 6, 9, 11, and 13) were flagged as homozy-
gous and three samples were flagged to contain closely related
alleles (4, 6, and 7) meaning that these should undergo validation
sequencing.
HLA typing of 18 cell lines (Table 4) included eight from
the International Histocompatibility Working Group (IHWG)
anthropology panel. This panel represented a broad diver-
sity of world samples and contained several rare alleles (fre-
quency< 0.1%, e.g., C*07:06, B*39:09, B*27:09, B*44:04, C*07:18,
C*12:05, and C*15:04, respective samples 26, 33, 37, 34, 30, and 25)
and several samples that contained closely related alleles (samples
22, 28, and 35 with B44, C7, and B27, respectively). Seven samples
(13, 24, 25, 27, 29, 31, 35, and 36) were homozygous for at least
one locus. Excluding A*24:33 (probes not present on the array),
three of the 107 alleles were incorrectly typed, all of them flagged
for validation sequencing.
In addition to two frozen blood samples that were repeated in
four arrays (Table 3), nine cell lines were typed as repeats, ranging
from 1 to 3 repeats, a total of 24 arrays (Table 5). The first instance
of triple homozygous cell line AMALA (sample 48, C*03:03) was
mistyped as HLA*C*03:03/12:02, while subsequent repeats were
correctly typed. All typing errors were in homozygous cell lines or
heterozygous cell lines that have closely related HLA alleles that
differ by up to three nucleotides. Typing accuracy of heterozygous
samples was 100%. The typing error sources were:
• Heterozygous samples with two highly similar variants – sam-
ples 22, 28, and 35 were mistyped as homozygous.
• Homozygous samples with probe masking – e.g., sample 4
homozygous at A locus for A*02:01 had signals from B
and C allele probes identical to HLA-A*02:16, resulting in
A*02:01/02:16 assignment (Figure 2D).
• Mistaken assignment within the same serotype, e.g., sample 13
that has C*07:06 was assigned *07:01.
• Wrong allele of other serotype assigned to homozygous sam-
ples, such as sample 48 where C*03:03/12:02 was assigned to a
homozygous C*03:03 sample.
• Missing allele because the probes do not exist on the array –
sample 30 was incorrectly typed because probes specific for
HLA-A*24:33 were not included in the array.
• Heavily degraded samples will result in typing errors. Sample
68 (Table S2 in Supplementary material) that has C*06:02/18:01
was assigned C*04:01/06:02. This sample had a very low mean
signal, three times lower than an average sample (829 relative
fluorescence units “RFU” vs. observed average of 2,519 RFU).
• Mixed samples will almost always result in typing errors,
except when two homozygous samples are mixed – Table S2
in Supplementary material.
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Table 3 | Blood samples used in this study.
Sample DFCI-ID HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C Sample type Status/actual
1 02 01:01 24:02 08:01 27:05 02:02 07:01 Blood OK
2 04 03:01 30:01 35:03 Nil 04:01 Nil Blood OK
3 05 01:01 24:02 27:07 52:01 12:02 15:02 Blood OK
4 06 02:01 02:16 07:02 27:05 02:02 07:02 Blood A*02:01/02:01
5 08 02:06 30:01 13:02 35:01 03:03 06:02 Blood OK
6 09 01:01 Nil 07:02 08:01 07:01 07:02 Blood OK
7 10 02:01 31:01 07:02 51:01 15:02 15:05 Blood OK
8 11 24:02 66:01 27:05 44:02 01:02 05:01 Blood OK
9 12 02:01 30:02 15:01 50:01 04:01 Nil Blood OK
10 13 11:02 33:03 44:03 52:01 12:02 14:03 Blood OK
11 14 02:01 Nil 18:01 40:02 02:02 07:01 Blood OK
12 15 01:01 11:01 07:02 52:01 07:02 12:02 Blood OK
13 16 33:03 Nil 44:03 Nil 07:01 14:03 Blood C*07:06
14 17 02:01 33:03 40:06 58:01 03:02 08:01 Blood OK
15 18 24:02 31:01 46:01 52:01 01:02 12:02 Blood OK
16 19 02:01 03:01 07:02 50:01 06:02 07:02 Blood OK
17 20 11:01 33:03 15:02 58:01 03:02 08:01 Blood OK
18 67 11:02 33:03 35:01 44:03 03:03 14:03 FB 1 OK
19 66 31:01 33:03 40:01 44:03 07:02 14:03 FB 2 OK
20 68 11:02 33:03 35:01 44:03 03:03 14:03 FB 1 repeat OK
21 75 31:01 33:03 40:01 44:03 07:02 14:03 FB 2 repeat OK
Blood samples are either newly collected blood (Blood) or frozen blood (FB). The FB samples have two replicates taken at different points in time (12 and 24 months
earlier). HLA-A, -B, and -C show assigned alleles.The correct HLA typing is in black font, the incorrect typing is shown in red.The actual alleles, if incorrectly assigned,
are shown in column Status/Actual, or designated “OK” if correct.
Table 4 | Cell line samples used in this study.
Sample DFCI-ID HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C Sample name Status/actual
22 40 26:01 29:02 Nil 44:03 05:01 16:01 1362-8572 (I) B*44:02/44:03
23 29 01:01 24:02 08:01 15:01 03:03 07:01 FH15 (I) OK
24 31 02:04 Nil 51:01 Nil 15:02 Nil RML (I) OK
25 35 24:02 Nil 15:17 51:01 07:01 15:04 BRIP (I) OK
26 37 24:02 29:02 39:09 44:03 07:02 16:01 FH24 (I) OK
27 38 29:02 Nil 14:02 57:01 06:02 08:02 MYE 2004 (I) OK
28 39 01:01 02:01 07:02 08:01 07:01 Nil FH53 (I) C*07:01/07:02
29 43 Nil 11:01 37:01 58:01 03:02 06:02 WUZH1 (I) OK
30 44 11:01 Nil 27:06 51:06 03:04 12:05 FH46 (I) HLA-A*24:33
31 23 02:16 03:01 Nil 51:01 07:04 15:02 TUBO (A) OK
32 26 31:01 33:01 14:02 35:02 04:01 08:02 FH3 (A) OK
33 27 02:01 29:02 27:09 44:03 01:02 16:01 FH5 (A) OK
34 30 02:05 68:02 14:02 58:01 07:18 08:02 FH1 (A) OK
35 32 01:01 Nil Nil 27:05 02:02 Nil FH4 (A) B*27:03/27:05
36 33 02:01 Nil 35:03 Nil 12:03 Nil KOSE (A) OK
37 42 01:01 68:01 15:01 44:04 06:02 16:01 1347-4843 (A) OK
38 46 02:03 11:01 38:02 46:01 07:02 12:02 LCK (A) OK
39 21 02:01 31:01 40:01 51:01 01:02 03:04 T1 OK
Cell line sample are from the IHWG anthropology panel, designated by (A), or other IHWG cell lines (I). The correct HLA typing is in black font, the incorrect typing is
shown in red. The actual alleles, if incorrectly assigned, are shown in column Status/Actual, or designated OK if correct.
In summary, samples typed by our method to have two variants
within the same serotype, or typed as homozygous should be vali-
dated by confirmatory typing using RNA or DNA sequencing. This
will initially account for approximately 30% of the samples. The
need for confirmatory sequencing will diminish as the number of
templates in the knowledgebase increases.
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Table 5 | Cell line repeats used in this study.
Sample DFCI-ID HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C Sample name Status/actual
40 22 02:01 25:01 13:02 38:01 06:02 12:03 LAZ509 OK
41 53 02:01 25:01 13:02 38:01 06:02 12:03 LAZ509 rep 1 OK
42 54 02:01 25:01 13:02 38:01 06:02 12:03 LAZ509 rep 2 OK
43 57 02:01 25:01 13:02 38:01 06:02 12:03 LAZ509 rep 3 OK
44 50 30:01 Nil 13:02 Nil 06:02 Nil LBF OK
45 65 30:01 Nil 13:02 Nil 06:02 Nil LBF rep 1 OK
46 74 30:01 Nil 13:02 Nil 06:02 Nil LBF rep 2 OK
47 77 30:01 Nil 13:02 Nil 06:02 Nil LBF rep 3 OK
48 24 02:17 Nil 15:01 Nil 03:03 12:02 AMALA C*03:03/03:03
49 63 02:17 Nil 15:01 Nil 03:03 Nil AMALA rep 1 OK
50 69 02:17 Nil 15:01 Nil 03:03 Nil AMALA rep 2 OK
51 49 03:01 11:01 40:01 Nil 03:04 Nil FH14 (A) OK
52 34 03:01 11:01 40:01 Nil 03:04 Nil FH14 rep OK
53 45 02:02 02:05 15:01 49:01 03:03 07:01 1416-1188 (A) OK
54 60 02:01 02:05 15:01 49:01 03:03 07:01 1416-1188 rep OK
55 28 30:01 68:02 Nil 42:01 17:01 Nil RSH (A) OK
56 70 30:01 68:02 42:01 Nil 17:01 Nil RSH rep OK
57 36 66:01 Nil 38:01 Nil 12:03 Nil TEM OK
58 71 66:01 Nil 38:01 Nil 12:03 Nil TEM rep OK
59 41 02:01 11:01 27:02 35:03 02:02 12:03 LUCE OK
60 47 02:01 11:01 27:02 35:03 02:02 12:03 LUCE rep 1 OK
61 76 02:01 11:01 27:02 35:03 02:02 12:03 LUCE rep 2 OK
62 61 02:06 02:07 46:01 Nil 01:02 08:01 T7526 OK
63 73 02:06 02:07 46:01 Nil 01:02 08:01 T7526 rep OK
Repeats are designated by “rep” in column Sample name.The correct HLA typing is in black font, the incorrect typing is shown in red.The actual alleles, if incorrectly
assigned, are shown in column Status/Actual, or designated OK if correct.
REPRODUCIBILITY OF RESULTS
The reproducibility was assessed using repeat samples (Table 5)
and repeat probes (data not shown). The array-wide probe sig-
nals showed high reproducibility with the majority of repeats
showing r > 0.975 for each pair of arrays hybridized with the
same samples (31 of 47) and r ≤ 0.975 for the arrays with dif-
ferent samples (all 879 pairs) (Figure 3). Three negative control
examples were correctly assigned (Table S2 in Supplementary
material) while the A*02:01 transgenic mouse sample was identi-
fied as negative because array-wide signals were low. Only a single
sample (sample 48) was mistyped in one of the three repeats
(Table 5). This sample was homozygous for C*03:03 but was
assigned C*03:03/C*12:02. The results indicate that the microar-
ray technology and sample processing can be standardized and
used in a high-throughput fashion. Array matching was done
by calculating overall correlation coefficients between the query
array signals and the template array signals stored in the knowl-
edgebase. All array pairs having r > 0.975 represented identical
samples; they were the highest matches within the set of tem-
plates. Rare examples where the array signals correlation coef-
ficients were high, but were mismatches, were rejected by the
serotype determination algorithm (Figure 3). These results indi-
cate that as the knowledgebase of templates grows, the majority
of the HLA typing will be directly readable from the template
matching.
DISCUSSION
The high-throughput methods such as next generation DNA (12)
and RNA (13) sequencing are alternative HLA typing approaches.
DNA sequencing has advantages: sample preparation is simple,
actual sequence can be directly read, and null alleles and previ-
ously unknown sequences can be identified. The disadvantages
include long reads, long turnaround time, and multiplexing –
samples are labeled and then mixed before they are read, creating
potential errors. The cost of DNA sequencing is relatively high
without multiplexing. RNA sequencing has advantages: actual
coding sequences are read directly, turnaround time is shorter, cost
is lower than DNA sequencing and new sequences can be identi-
fied. The disadvantages include multiplexing and some sequencing
ambiguities. The advantages of microarray-based typing include
rapid turnaround, individual handling of each sample, and the
establishment of a knowledgebase that improves the quality of
HLA typing as it grows. This method is amenable to automation.
The disadvantages of microarray approach include the lack of abil-
ity to identify novel sequences and the need to deal with masking
problems. Samples that are homozygous or have two closely related
alleles need to be confirmed by sequencing.
Bone marrow transplantation (BMT) is a treatment of choice
in a spectrum of hematological malignancies, aplastic anemia,
immunodeficiencies, hemoglobulinopathies, and inherited dis-
eases, such as metabolic disorders and osteopetrosis. Recent
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reports suggest that viral clearance from HIV-positive indi-
viduals can be achieved using the BMT (23). The success
rate of allogeneic BMT has steadily increased over the last
40 years, largely due to the HLA matching between donor and
recipient (3, 24–26).
Drug toxicity associations with HLA have been known for
several decades (7). Apart from the B*57:01-associated Aba-
cavir hypersensitivity syndrome (ASH) (27) there is a myriad of
reported drug toxicity associations. The anticonvulsant Carba-
mazepine can cause Stevens–Johnson Syndrome in HLA-B*15:02,
B*15:11, B*15:18, A*30:10, A*31:01, and C*07:04 in a population-
specific manner (28–36). A detailed listing of HLA associations
with drug toxicity is shown in Table S7 in Supplementary mate-
rial (7, 37–47). Precision HLA typing is important because sin-
gle amino acid differences often define functional haplotypes
whose differences may result in serious consequences. For example
B*27:05 confers susceptibility to spondyloarthropaties (48) while
B*27:03 is protective. These two alleles differ at a single nucleotide
position 247 (exon 2, see Figure 1B) that codes for tyrosine in
B*27:05 and histidine in B*27:03 (Y83H). This change modifies
pocket F that binds a major anchor of HLA ligands and result in
different peptide repertoires for B*27:05 and B*27:03. Abacavir
toxicity is observed in HLA-B*57:01 individuals but not in indi-
viduals with the related allele B*57:03 that differs in two nucleotide
positions at positions 340 (exon 2) and 347 (exon 3) causing dif-
ferential drug binding and a resultant change in peptide repertoire
upon Abacavir binding to HLA-B*57:01 (49, 50). Similarly, a major
conserved T-cell epitope from human papilloma virus E7 antigen
is presented by A*02:01, but not by A*02:07 (common in Asians).
These two alleles differ in nucleotide position 296 (exon 2) result-
ing in a single amino acid change (Y99C) affecting the binding
of peptide primary anchor P2. These examples suggest that the
mechanism underlying these associations can be traced to fine
differences in the binding groove altering the repertoires of HLA-
presented peptides. They illustrate the importance of the precision
and accuracy of HLA typing since small differences, even a single
amino acid substitution, can have profound functional and clinical
effects.
Human leukocyte antigens associations have been studied in
more than 100 diseases including autoimmunity, allergy, infec-
tions, and cancer. Strong associations have been shown for
rheumatoid arthritis, type 1 diabetes, celiac disease, inflamma-
tory bowel disease, multiple sclerosis, autoimmune thyroid disease,
psoriasis, ankylosing spondylitis, systemic lupus erythematosus,
juvenile reactive arthritis and vitiligo (28, 31, 32, 34, 35). HLA
associations have been reported in response to vaccines and spe-
cific mechanisms have yet to be described. Lower level of measles
antibodies were observed in the HLA-B7 supertype individuals
(51). Frequencies of HLA-A11 and -A24 were higher in Hepati-
tis B vaccine non-responders than in the responder group (52).
HLA is used as a marker in population studies (53), elucidation
of ancestry (54), tracking human migrations (19), prenatal testing
(55), forensic science (56), human evolution genetics studies (57),
and host-pathogen co-evolution (2, 58).
Human leukocyte antigens is such an important biomarker
that the entire human population should be tissue typed, simi-
larly as blood types are determined today. Combining HLA data
with clinical records will have profound effects for the control of a
variety of diseases. HLA typing is particularly important in clini-
cal studies that involve immunology, HLA-related diseases, various
cancers, and infectious disease. Many drugs that have failed clin-
ical trials because of side effects can be re-examined for possible
HLA-related toxicity. We estimate that in 70% of samples direct
matching will be achieved by comparison with the knowledgebase
templates. The remaining 30% of samples will be further validated
by targeted sequencing, typically using a single locus sequencing
run. Clinical records with the individuals’ HLA will allow iden-
tification of HLA disease associations, drug toxicity, and other
clinically relevant associations. HLA typing is another frontier that
will be conquered by advanced biotechnologies with computa-
tional methods. Population-wide HLA typing will have significant
implications for personalized care and the improvement of public
health.
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